3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.

about

3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.

Item

http://www.wikidata.org/entity/Q39575305

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

3M-052 as an adjuvant for a PL ...... i recombinant protein vaccine.

@en

3M-052 as an adjuvant for a PL ...... i recombinant protein vaccine.

@nl

type

Item

label

3M-052 as an adjuvant for a PL ...... i recombinant protein vaccine.

@en

3M-052 as an adjuvant for a PL ...... i recombinant protein vaccine.

@nl

prefLabel

3M-052 as an adjuvant for a PL ...... i recombinant protein vaccine.

@en

3M-052 as an adjuvant for a PL ...... i recombinant protein vaccine.

@nl

P1476

3M-052 as an adjuvant for a PL ...... i recombinant protein vaccine.

@en

P2093

C Patrick McAtee

http://www.w3.org/2001/XMLSchema#string

Christopher A Seid

http://www.w3.org/2001/XMLSchema#string

Elissa M Hudspeth

http://www.w3.org/2001/XMLSchema#string

Michael J Heffernan

http://www.w3.org/2001/XMLSchema#string

Qian Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

Current advances in research and clinical applications of PLGA-based nanotechnology.

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

Imiquimod and resiquimod as novel immunomodulators.

Vaccines to prevent leishmaniasis.

Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3

The immunology of susceptibility and resistance to Leishmania major in mice.

P31

scholarly article

P356

10.1002/JBM.B.33965

http://www.w3.org/2001/XMLSchema#string

P50

Meagan A Barry

P577

2017-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28804955

http://www.w3.org/2001/XMLSchema#string